Articles by Nick Paul Taylor
Last winter, Google Flu Trends was shown to be a work in progress when it wildly overestimated incidence of influenza, but its algorithm-based model has considerable potential.
Biopharma researchers have accrued a huge library of chemical safety data over the past 60 years, but--as is often the case--much of it is tied up in formats that make computational analysis impossible.
The United Kingdom is moving heavily into sequencing through its 100K Genome Project, but the data is of little use without analytical abilities. With this in mind, the U.K. government has coughed up an extra $16 million to find genomics sequence data analysis and interpretation tools.
With the end of 2013 nearing, market analysts are looking back on the year and forecasting what is next for the industry. Shared, familiar themes are emerging: Biopharma is still struggling to make R&D more productive, and observers are still talking up the potential for technology to ease the industry's woes.
Poor returns led drug developers to exit the antibiotics sector years ago, only for hospital-acquired infections to become a big, deadly and potentially lucrative problem. Big Pharma is returning to the sector, but two academics have a different idea: crowdsource discovery.
With pressure mounting on drugmakers to make clinical trial data more transparent, Pfizer has started to take steps to open up its results, unveiling more concrete details and a timeline for adoption this week.
After suffering a string of late-phase failures in recent years, Merck KGaA is in the middle of restructuring its business and rebuilding its pipeline. This week, the company began working with two potential sources of new drugs when computational biology and antibody discovery startups joined its Israeli bio incubator.
Since 1888, the U.S. has published weekly reports on cases of notifiable diseases, building a huge trove of data in the process. The usefulness of this data was limited by its format, which stopped researchers from effectively mining it for insights, but a massive digitization project has now opened up the information.
When Pfizer began its virtual trial in 2011, the technology it used was at the forefront of innovation in clinical research. Yet two years later, some of the ideas are already looking dated, with the rise of smartphones meaning Pfizer now foresees participants using their own devices, instead of dedicated tools.
Sony has filed a patent for a "SmartWig," a replacement head of hair that also tracks the wearer's blood pressure, temperature and other metrics.